DrugPatentWatch Database Preview

AEMCOLO Drug Profile

« Back to Dashboard

Which patents cover Aemcolo, and when can generic versions of Aemcolo launch?

Aemcolo is a drug marketed by Redhill and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-seven patent family members in twenty countries.

The generic ingredient in AEMCOLO is rifamycin sodium. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rifamycin sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Aemcolo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 3, 2025. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for AEMCOLO

International Patents:	27
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	2
Patent Applications:	3,154
Drug Prices:	Drug price information for AEMCOLO
What excipients (inactive ingredients) are in AEMCOLO?	AEMCOLO excipients list
DailyMed Link:	AEMCOLO at DailyMed

See drug prices for AEMCOLO

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for AEMCOLO

NDA:

210910

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AEMCOLO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bradley A. Connor, M.D.	Phase 2
Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2

See all AEMCOLO clinical trials

Pharmacology for AEMCOLO

Drug Class

Rifamycin Antibacterial

US Patents and Regulatory Information for AEMCOLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Redhill	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y
Redhill	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y
Redhill	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y
Redhill	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y

International Patents for AEMCOLO

Country	Patent Number	Estimated Expiration
South Africa	200610577
Slovenia	1763339
Canada	2569683
Mexico	PA06014698
Cyprus	1108196
World Intellectual Property Organization (WIPO)	2006003043
Japan	5026262

Supplementary Protection Certificates for AEMCOLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1763339	C201930053	Spain		PRODUCT NAME: RIFAMICINA SV; NATIONAL AUTHORISATION NUMBER: 84120-DE/H/5379/001/DC; DATE OF AUTHORISATION: 20190628; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): PL 08637/0028; DATE OF FIRST AUTHORISATION IN EEA: 20181218
1763339	122019000048	Germany		PRODUCT NAME: RIFAMYCIN SV; NAT. REGISTRATION NO/DATE: 2200986.00.00 20190509; FIRST REGISTRATION: GB PL 08637/0028 20181218